The effect of estramustine phosphate on prostatic cancer estimated by transrectal ultrasonotomography.
Transrectal ultrasonotomography was performed in 44 patients with prostatic cancer before, during, and after estramustine phosphate (Estracyt) administration. In 75.7% of 37 previously untreated patients, the deformity of the horizontal section of the prostate with prostatic cancer was corrected considerably, while in 89.2%, prostatic weight was remarkably reduced. In 57.1% of seven previously treated patients, appreciable changes were also observed in the shape and weight of the prostate. We concluded that estramustine phosphate was effective not only for untreated prostatic cancer, but also, at least in some degree, for relapsed cases.
D000368:Aged; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000033:anatomy & histology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012007:Rectum; D014463:Ultrasonography
D009588:Nitrogen Mustard Compounds; D004961:Estramustine